查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594698

口服疫苗市場：按類型、應用和最終用戶分類 - 2025-2030 年全球預測

Oral Vaccine Market by Type (Attenuated, Inactive), Application (Cholera, Polio, Rabies), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年口服疫苗市場規模為168.3億美元，預計2024年將達到179.1億美元，複合年成長率為6.48%，2030年將達261.4億美元。

口服疫苗市場包括用於預防感染疾病的口服疫苗的開拓、生產和分銷，特別是在傳統注射疫苗造成物流挑戰的地區。口服疫苗可以提高免疫率，因為它們不需要針頭或經過訓練的醫護人員。口服疫苗廣泛用於免疫計劃中，以對抗輪狀病毒和霍亂等引起腹瀉的病原體，該技術也正在針對流感和 COVID-19 等其他感染疾病進行研究。最終用途範圍主要包括公共衛生舉措、醫療保健設施和與旅行相關的衛生部門。感染疾病的日益普及、新興國家對大規模免疫策略的需求以及口服疫苗技術的進步推動了市場的開拓。新的商機源自於大規模研發投資、免疫計畫的更多採用以及傳訊RNA(mRNA) 技術在口服疫苗開發中的潛在整合。

主要市場統計
基準年[2023] 168.3億美元
預測年份 [2024] 179.1億美元
預測年份 [2030] 261.4億美元
複合年成長率（%） 6.48%

此外，市場參與者應專注於與政府和非政府組織（NGO）合作，以加強低收入地區的分配。然而，監管障礙、口服製劑的穩定性和功效問題以及公眾對口服疫苗功效的懷疑等挑戰可能會阻礙成長。在農村和人煙稀少的地區，基礎設施和低溫運輸物流的限制更是一個障礙。為了利用市場機會，上市公司將優先考慮耐熱疫苗配方的創新，擴大對新型佐劑的研究以提高功效，並加強公眾教育宣傳活動以打擊錯誤訊息。奈米顆粒和微針技術的創新可實現更好的口服給藥，可顯著增強市場動態。由於市場的性質受到衛生政策和全球衛生措施的強烈影響，針對合資企業和靈活製造能力的投資的策略規劃將有助於確保適應動態的市場需求並有效利用成長機會。

市場動態：快速發展的口服疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變口服疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 製藥業對無針疫苗的需求快速成長
    • 感染疾病增加
    • 增加具有成本效益的口服疫苗的生產和供應
  • 市場限制因素
    • 口服疫苗的開發和儲存成本較高
  • 市場機會
    • 加大口服疫苗產品的開發力度
    • 口服疫苗在野生動物疾病管理的潛力
  • 市場挑戰
    • 與使用口服疫苗相關的副作用

波特五力：駕馭口服疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解口服疫苗市場的外部影響

外部宏觀環境因素在塑造口服疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解口服疫苗市場的競爭狀況

對口服疫苗市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣口服疫苗市場供應商的績效評估

FPNV定位矩陣是評估口服疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製口服疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，口服疫苗市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 製藥業對無針疫苗的快速需求
      • 感染疾病率增加
      • 增加具有成本效益的口服疫苗的生產和供應
    • 抑制因素
      • 開發和儲存口服疫苗的成本高昂
    • 機會
      • 口服疫苗產品研發進展
      • 口服疫苗控制野生動物疾病的潛力
    • 任務
      • 與使用口服疫苗相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章口服疫苗市場：依類型

  • 衰減
  • 不活躍的

第7章口服疫苗市場：依應用分類

  • 霍亂
  • 脊髓灰質炎
  • 狂犬病
  • 呼吸道感染疾病
  • 結核

第8章口服疫苗市場：依最終用戶分類

  • 診所
  • 醫院

第9章美洲口服疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太口服疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲口服疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Biogen Inc.
  • Bull Bio-NCIPD Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Janssen Global Services, LLC
  • Lumen Bioscience, Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shanghai BravoBio Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Vaxart, Inc.
  • Zoetis Inc.
Product Code: MRR-035DA3C63714

The Oral Vaccine Market was valued at USD 16.83 billion in 2023, expected to reach USD 17.91 billion in 2024, and is projected to grow at a CAGR of 6.48%, to USD 26.14 billion by 2030.

The scope of the oral vaccine market encompasses the development, production, and distribution of vaccines administered orally to prevent infectious diseases, particularly in regions where traditional injectable vaccines face logistical challenges. Oral vaccines are crucial due to their ease of administration, which enhances immunization coverage by eliminating the need for needles and trained medical personnel. They are extensively used in immunization programs to combat diarrhea-causing pathogens like rotavirus and cholera, and the technology is being explored for other infections like influenza and COVID-19. The end-use scope primarily includes public health initiatives, healthcare facilities, and travel-related health sectors. Market growth is driven by the increasing prevalence of infectious diseases, need for mass immunization strategies in developing regions, and advancements in oral vaccine technology. Emerging opportunities stem from significant R&D investments, the rising adoption of immunization programs, and the potential integration of messenger RNA (mRNA) technology for developing oral vaccines.

KEY MARKET STATISTICS
Base Year [2023] USD 16.83 billion
Estimated Year [2024] USD 17.91 billion
Forecast Year [2030] USD 26.14 billion
CAGR (%) 6.48%

Additionally, market players should focus on partnerships with governments and non-governmental organizations (NGOs) to enhance distribution in low-income regions. However, challenges such as regulatory hurdles, the stability and efficacy issues of oral formulations, and public skepticism toward oral vaccine effectiveness can impede growth. Limitations in infrastructure and cold chain logistics further pose barriers in rural and underdeveloped areas. To capitalize on market opportunities, companies should prioritize innovation in thermal-stable vaccine formulations, expand research into novel adjuvants to improve efficacy, and reinforce public education campaigns to combat misinformation. Innovations in nanoparticle and microneedle technologies for better oral delivery can significantly enhance market dynamics. As the market nature is highly influenced by health policies and global health initiatives, strategic planning aligned toward collaborative ventures and investment in flexible manufacturing capabilities can ensure adaptability to dynamic market demands, harnessing growth opportunities effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oral Vaccine Market

The Oral Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in the demand for needle-free vaccines by the pharmaceutical industry
    • Growing incidences of infectious diseases
    • Increasing production and availability of cost-effective oral vaccines
  • Market Restraints
    • High cost of development and storage of the oral vaccine
  • Market Opportunities
    • Rising development in the oral vaccines products
    • Potential of oral vaccines for disease control in wildlife species
  • Market Challenges
    • Side effects associated with the use of oral vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Oral Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oral Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oral Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oral Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oral Vaccine Market

A detailed market share analysis in the Oral Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oral Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oral Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oral Vaccine Market

A strategic analysis of the Oral Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oral Vaccine Market, highlighting leading vendors and their innovative profiles. These include Biogen Inc., Bull Bio - NCIPD Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Janssen Global Services, LLC, Lumen Bioscience, Inc., Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai BravoBio Co., Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Vaxart, Inc., and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Oral Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Attenuated and Inactive.
  • Based on Application, market is studied across Cholera, Polio, Rabies, Respiratory Infection, and Tuberculosis.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the demand for needle-free vaccines by the pharmaceutical industry
      • 5.1.1.2. Growing incidences of infectious diseases
      • 5.1.1.3. Increasing production and availability of cost-effective oral vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development and storage of the oral vaccine
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising development in the oral vaccines products
      • 5.1.3.2. Potential of oral vaccines for disease control in wildlife species
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the use of oral vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oral Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated
  • 6.3. Inactive

7. Oral Vaccine Market, by Application

  • 7.1. Introduction
  • 7.2. Cholera
  • 7.3. Polio
  • 7.4. Rabies
  • 7.5. Respiratory Infection
  • 7.6. Tuberculosis

8. Oral Vaccine Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Oral Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oral Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oral Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biogen Inc.
  • 2. Bull Bio - NCIPD Ltd.
  • 3. F. Hoffmann-La Roche Ltd.
  • 4. GlaxoSmithKline PLC
  • 5. Janssen Global Services, LLC
  • 6. Lumen Bioscience, Inc.
  • 7. Novo Nordisk A/S
  • 8. Pfizer Inc.
  • 9. Sanofi S.A.
  • 10. Serum Institute of India Pvt. Ltd.
  • 11. Shanghai BravoBio Co., Ltd.
  • 12. Takeda Pharmaceutical Company Limited
  • 13. Valneva SE
  • 14. Vaxart, Inc.
  • 15. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. ORAL VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. ORAL VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ORAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ORAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORAL VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY CHOLERA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ORAL VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023